David Dale is a Hematologist Oncology expert in Seattle, Washington. Dale has been practicing medicine for over 57 years and is rated as an Elite expert by MediFind in the treatment of Chronic Familial Neutropenia. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Chronic Familial Neutropenia, Agranulocytosis, Infantile Neutropenia, Cyclic Neutropenia, and Bone Marrow Transplant. He is licensed to treat patients in Washington. Dale is currently accepting new patients.
Helen Papadaki practices in Irakleion, Greece. Papadaki is rated as an Elite expert by MediFind in the treatment of Chronic Familial Neutropenia. She is also highly rated in 19 other conditions, according to our data. Her top areas of expertise are Chronic Familial Neutropenia, Idiopathic Neutropenia, Agranulocytosis, Bone Marrow Transplant, and Endovascular Embolization.
Irene Mavroudi practices in Irakleion, Greece. Mavroudi is rated as an Elite expert by MediFind in the treatment of Chronic Familial Neutropenia. She is also highly rated in 3 other conditions, according to our data. Her top areas of expertise are Idiopathic Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant.
Background: CTLA4 stands for cytotoxic T-lymphocyte antigen-4. It is a protein the body makes naturally to check its immune system from attacking itself. Some people don t produce enough CTLA4 protein, causing problems due to overactive immune system such as big spleens, repeated lung infections, breathing problems, stomach and intestine symptoms as well as inflamed brain and nerve problems. Many have problem...
Summary: This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people living with chronic neutropenia (including congenital, idiopathic, and cyclic). In Part 2 (Phase 2), the safety and tolerability of chronic dosing of mavorixafor will be eva...